Exclusive Summary

• The differentiated 0.075mg low-dose allows for precise titration and minimizes side effects in elderly and pediatric populations, enabling distributors to bypass the red-ocean price wars of standard 0.1mg/0.2mg strengths.
• Targets the 10%-20% resistant hypertension segment among 1.28 billion global patients, while capturing significant off-label demand in pediatric ADHD (affecting 5-8% globally).
• With no patent barriers and supported by China's highly cost-effective API-to-finished-dose supply chain and ready CTD dossiers, distributors can achieve rapid local registration and high-margin commercialization.